Cambodia on verge of achieving malaria-free goal: PM Hun
In a message to mark the National Malaria Day on Friday, he said the Southeast Asian country reported only 355 malaria cases in 2024, a significant drop of 75 per cent compared to 2023.
The prime minister added that the kingdom had reported zero deaths from the disease since 2018 and no local Plasmodium Falciparum cases since 2024.
"Cambodia is on the verge of achieving a malaria-free goal by the end of 2025," Hun Manet said, urging all stakeholders to continue to support the country to achieve the target.
Huy Rekol, director of the National Center for Parasitology, Entomology and Malaria Control, said malaria diagnostic tests and treatments have been highly effective in Cambodia, with Artesunate/Mefloquine, or ASMQ, being 100 per cent safe and efficacious against malaria, Xinhua news agency reported.
"This progress has put Cambodia in the category of successful countries in eliminating malaria," he told Xinhua.
Malaria is a mosquito-borne infectious disease that is typically found in forest and mountainous provinces, especially during rainy seasons.
To avoid being bitten by malaria-carrying mosquitoes, Rekol advises people living in malaria-risk areas to sleep under insecticide-treated mosquito nets at all times.
Symptoms can be mild or life-threatening. Mild symptoms are fever, chills and headache. Severe symptoms include fatigue, confusion, seizures, and difficulty breathing.
Infants, children under 5 years, pregnant women and girls, travellers and people with HIV or AIDS are at higher risk of severe infection.
Malaria can be prevented by avoiding mosquito bites and with medicines. Treatments can stop mild cases from getting worse.
Malaria mostly spreads to people through the bites of some infected female Anopheles mosquitoes. Blood transfusion and contaminated needles may also transmit malaria.
The first symptoms may be mild, similar to many febrile illnesses, and difficulty to recognise as malaria.
Left untreated, P. falciparum malaria can progress to severe illness and death within 24 hours.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
7 hours ago
- Time of India
Who is Anjani Sinha, the Indian-origin surgeon nominated by Donald Trump as Singapore's ambassador?
Source: X Dr. Anjani Sinha, President Donald Trump 's nominee for U.S. Ambassador to Singapore, faced pointed criticism during his Senate confirmation hearing on July 9, after failing to answer several fundamental questions about the Southeast Asian nation and U.S. strategic interests in the Indo-Pacific region. Senator Tammy Duckworth pressed a seasoned orthopedic surgeon with no prior diplomatic experience, Sinha, on Singapore's trade surplus with the U.S., its role in ASEAN, and the strategic presence of the U.S. Navy in the region. His responses were inconsistent and at times inaccurate. The exchange quickly became tense, with Duckworth accusing Sinha of viewing the posting as a 'glamour job,' saying: 'You are not currently prepared for this posting, period, and you need to shape up and do some homework.' She added, 'You think this is a glamour posting, that you're going to live a nice life in Singapore, when what we need is someone who can actually do the work.' Who is Anjani Sinha? Despite the controversy surrounding his nomination, Dr. Anjani Sinha has had a long and accomplished career in medicine and business. He is a highly respected orthopedic surgeon and entrepreneur who has built multiple thriving medical practices across the United States. Early Life and Education Born in Bihar, India, Dr. Sinha earned his medical degree from Mahatma Gandhi Medical College. In 1972, he relocated to New Delhi, completing his residency at Safdarjung Hospital, affiliated with Delhi University and the Central Institute of Orthopaedics. In 1979, Dr. Sinha migrated to the United States. He interned at top institutions including Mount Sinai Medical Center and Long Island Jewish Medical Center, gaining a strong foundation in American medical practice. He would later specialize in orthopedic surgery and sports medicine. Career Dr. Sinha has established a prominent presence on the East Coast, building key-man orthopedic and surgical practices across eight locations in New York. He has also served as a senior surgical consultant in Florida. His work spans both the public and private sectors, interfacing with professionals across healthcare, business, and legal fields. Family and personal life Dr. Sinha has been married for 48 years to Dr. Kuntala 'Kiki' Sinha, a retired anesthesiologist and former faculty member at NYU. The couple became U.S. citizens in the mid-1990s after immigrating together in 1979. They have two children, Pooja (born 1981) and Sumeet (born 1983), both born in the United States. The Sinhas have embraced education as a core family value. Pooja is an alumna of Dartmouth and Harvard, while Sumeet studied at New York University and Columbia. They now have three grandchildren. As per The Edge Singapore, Dr. Sinha retains strong cultural and familial ties to India and the broader Indo-Pacific region. His extended family includes connections to Yashwant Sinha, a former Indian finance minister and the Opposition's candidate in India's 2022 presidential election.
Hans India
7 hours ago
- Hans India
Laos urges vigilance as dengue risk rises amid persistent rainfall
As persistent rainfall continues across Laos, health authorities urge the public to remain alert and take preventive measures against dengue fever. Although Laos has reported a significant drop in dengue cases, health officials warn that the risk remains high during the rainy season. They urge residents to participate in local clean-up efforts and practice home prevention measures to combat the spread of the disease. To further prevent dengue, local officials in many villages have organised collective activities that encourage authorities and villagers to work together to eliminate mosquito breeding sites around their homes. Mithouna, a Vientiane resident, actively participates in local clean-up efforts, Xinhua news agency reported. "My neighbours and I clean our homes and surroundings at least once a week. It's important for everyone to work together to reduce the risk of dengue fever, especially during continuous rainfall," Mithouna told Xinhua on Sunday. She stressed that dengue affects entire communities, not just individuals. "Dengue is a deadly disease, and it doesn't affect just one household. That's why I believe everyone needs to stay alert and take responsibility." Chanxay emphasised the importance of disease prevention, especially during the current period of continuous rainfall when many children are home on summer break. "The rain hasn't stopped, and water is collecting everywhere. On top of that, children are home from school, which makes this a very dangerous time for us," said Chanxay. "As parents, we have to be more careful than ever." As of July 21, Laos has reported 4,308 cases of dengue fever, including one death. The highest number of cases was recorded in the Lao capital, Vientiane, which reported 2,052 infections, according to the Ministry of Health. Health authorities recommend five effective dengue control measures for households - sealing unused containers, emptying water vessels, placing guppy fish in jars to consume mosquito larvae, cleaning around homes, and consistently performing these tasks weekly.
Indian Express
14 hours ago
- Indian Express
Knowledge Nugget: AdFalciVax and the fight against malaria — What you must-know for UPSC Exam
Take a look at the essential events, concepts, terms, quotes, or phenomena every day and brush up your knowledge. Here's your UPSC Current Affairs Knowledge Nugget for today on AdFalciVax and malaria. The Indian Council of Medical Research (ICMR) has invited the country's vaccine manufacturers to partner with it to launch and sell a malaria vaccine, AdFalciVax, that its Regional Medical Research Centre, Bhubaneshwar, has developed. In this context, let's know about this new vaccine and malaria. 1. AdFalciVax is a chimeric recombinant vaccine — a type of vaccine that uses different parts of the genes of a pathogen (in this case, Plasmodium) to create target proteins that trigger an immune response after being injected. 2. AdFalciVax uses two types of target proteins to prevent the spread of infection in two different ways. ↪ It uses the circumsporozoite protein (CSP) to prevent infection in the person who has been immunised. The CSP is produced during the sporozoite stage (when a parasite can infect a new host) and the liver stage (when a parasite enters liver cells, multiplies, and then infects red blood cells) of the parasite. 'Any immune response generated against these stages protects the immunised person from getting the infection.' Subhash Singh, project manager for development of the vaccine at the ICMR-Regional Medical Research Centre, Bhubaneswar told The Indian Express. ↪ The vaccine also uses the Pro6C protein, a fusion of parts of two different proteins — Pfs230 and Pfs48/45 — produced by Plasmodium falciparum. This protein prevents the spread of infection in the community. 3. Researchers have found that AdFalciVax provided more than 90% protection against infection in mice. The candidate vaccine has yet to undergo rigorous human trials, and the preliminary results have been obtained only through testing on animals. 4. The ICMR wants to partner with a company that can further develop its candidate vaccine, carry out human clinical trials, and scale up for commercial production. Although the ICMR will share the technology of developing AdFalciVax with the chosen company, it will continue to hold the intellectual property rights. Any intellectual property rights generated during the collaboration will be held jointly by the ICMR and the company. 5. Notably, AdFalciVax mainly targets two parts of Plasmodium falciparum, a pathogen that is the most common source of malaria in humans. In India, however, the disease is caused by Plasmodium vivax against which AdFalciVax is ineffective. To combat malaria, scientists have been working to develop a vaccine for decades but with limited success. Recently, two vaccines—RTS,S and R21—were approved for use, but their efficacy, at 75%, is quite low. That's why the announcement about ICMR's candidate vaccine has given new hope in the fight against the disease. World Malaria Day is observed every year on 25th April by the World Health Organisation to raise awareness and drive action against malaria. The theme for World Malaria Day 2025 is 'Malaria Ends With Us: Reinvest, Reimagine, Reignite.' 1. Having claimed millions of lives, malaria has been one of the deadliest diseases in human history. Currently, the disease kills about four lakh people annually, according to World Health Organization (WHO) figures. 2. Malaria is a parasitic infection transmitted by mosquitoes, typically causing symptoms such as fever, chills, night sweats, nausea, vomiting, and diarrhoea. In some cases, it can lead to severe complications such as seizures, fluid in the lungs, organ damage, and death. 3. It is most endemic in Africa — Nigeria, Congo, Tanzania, Mozambique, Niger, and Burkina Faso together account for more than half the yearly deaths. 1. India has demonstrated significant progress in reducing malaria cases and associated mortality in the country's high-endemic states, according to the findings of the World Health Organisation's (WHO) 'World Malaria Report 2024′. 2. 'India exited the HBHI [high-burden to high-impact] group officially in 2024 due to significant progress in reducing the malaria incidence and mortality observed in its high-endemic states,' the report observed. 3.'Nationwide, the number of estimated malaria cases in India decreased from 6.4 million in 2017 (the year before the HBHI's introduction) to 2 million cases in 2023 (69 per cent decrease). Similarly, the estimated malaria deaths decreased from 11,100 to 3,500 (68 per cent decrease) during the same period,' it said. 4. The HBHI refers to a targeted WHO initiative aimed at the most acutely malaria-impacted regions of the world, including several countries in Africa. Widespread resistance of malarial parasite to drugs like chloroquine has prompted attempts to develop a malarial vaccine to combat malaria. Why is it difficult to develop an effective malaria vaccine? (UPSC CSE 2010) (a) Malaria is caused by several species of Plasmodium (b) Man does not develop immunity to malaria during natural infection (c) Vaccines can be developed only against bacteria (d) Man is only an intermediate host and not the definitive host (Sources: India registers 'significant progress' in reducing malaria cases: WHO, WHO report says India reduces malaria caseload, deaths by 69% each) Subscribe to our UPSC newsletter. Stay updated with the latest UPSC articles by joining our Telegram channel – Indian Express UPSC Hub, and follow us on Instagram and X. 🚨 Click Here to read the UPSC Essentials magazine for July 2025. Share your views and suggestions in the comment box or at
